Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

NASDAQ:XFOR - Nasdaq - US98420X1037 - Common Stock - Currency: USD

3.4  -0.12 (-3.41%)

After market: 3.4 0 (0%)

Fundamental Rating

2

Taking everything into account, XFOR scores 2 out of 10 in our fundamental rating. XFOR was compared to 560 industry peers in the Biotechnology industry. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative. XFOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year XFOR has reported negative net income.
XFOR had a negative operating cash flow in the past year.
XFOR had negative earnings in each of the past 5 years.
In the past 5 years XFOR always reported negative operating cash flow.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

XFOR's Return On Assets of 11.23% is amongst the best of the industry. XFOR outperforms 94.82% of its industry peers.
The Return On Equity of XFOR (63.62%) is better than 98.93% of its industry peers.
Industry RankSector Rank
ROA 11.23%
ROE 63.62%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

Looking at the Profit Margin, with a value of 46.54%, XFOR belongs to the top of the industry, outperforming 99.11% of the companies in the same industry.
Looking at the Gross Margin, with a value of 82.42%, XFOR belongs to the top of the industry, outperforming 86.61% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 46.54%
GM 82.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XFOR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XFOR has been increased compared to 5 years ago.
XFOR has a worse debt/assets ratio than last year.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -7.43, we must say that XFOR is in the distress zone and has some risk of bankruptcy.
XFOR's Altman-Z score of -7.43 is on the low side compared to the rest of the industry. XFOR is outperformed by 68.21% of its industry peers.
A Debt/Equity ratio of 3.30 is on the high side and indicates that XFOR has dependencies on debt financing.
XFOR has a Debt to Equity ratio of 3.30. This is amonst the worse of the industry: XFOR underperforms 83.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.3
Debt/FCF N/A
Altman-Z -7.43
ROIC/WACCN/A
WACC10.97%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 3.70 indicates that XFOR has no problem at all paying its short term obligations.
XFOR has a Current ratio of 3.70. This is comparable to the rest of the industry: XFOR outperforms 42.32% of its industry peers.
XFOR has a Quick Ratio of 3.58. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XFOR (3.58) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.58
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

XFOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.90%, which is quite impressive.
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

XFOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.02% yearly.
Based on estimates for the next years, XFOR will show a very strong growth in Revenue. The Revenue will grow by 160.56% on average per year.
EPS Next Y47.3%
EPS Next 2Y26.95%
EPS Next 3Y22.49%
EPS Next 5Y15.02%
Revenue Next Year1063.28%
Revenue Next 2Y222.93%
Revenue Next 3Y271.98%
Revenue Next 5Y160.56%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XFOR. In the last year negative earnings were reported.
Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 22.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.95%
EPS Next 3Y22.49%

More info and screens

0

5. Dividend

5.1 Amount

XFOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (5/30/2025, 8:00:02 PM)

After market: 3.4 0 (0%)

3.4

-0.12 (-3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners58.44%
Inst Owner Change6.6%
Ins Owners4.78%
Ins Owner Change68.89%
Market Cap19.69M
Analysts83.64
Price Target49.98 (1370%)
Short Float %N/A
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.42%
Min EPS beat(2)-12.04%
Max EPS beat(2)100.88%
EPS beat(4)1
Avg EPS beat(4)-303.78%
Min EPS beat(4)-1301.88%
Max EPS beat(4)100.88%
EPS beat(8)3
Avg EPS beat(8)-155.06%
EPS beat(12)6
Avg EPS beat(12)-100.65%
EPS beat(16)7
Avg EPS beat(16)-78.4%
Revenue beat(2)2
Avg Revenue beat(2)674.26%
Min Revenue beat(2)35.03%
Max Revenue beat(2)1313.49%
Revenue beat(4)3
Avg Revenue beat(4)344.75%
Min Revenue beat(4)-67.57%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1737.48%
PT rev (3m)1556.36%
EPS NQ rev (1m)-2984.48%
EPS NQ rev (3m)-3471.48%
EPS NY rev (1m)-2000.19%
EPS NY rev (3m)-2086.44%
Revenue NQ rev (1m)-26.06%
Revenue NQ rev (3m)-39.61%
Revenue NY rev (1m)122.93%
Revenue NY rev (3m)104.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.46
EYN/A
EPS(NY)-8.27
Fwd EYN/A
FCF(TTM)-20.71
FCFYN/A
OCF(TTM)-18.94
OCFYN/A
SpS5.42
BVpS3.96
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.23%
ROE 63.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 46.54%
GM 82.42%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 3.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 848.51%
Cap/Sales 32.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.58
Altman-Z -7.43
F-Score4
WACC10.97%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.51%
EPS Next Y47.3%
EPS Next 2Y26.95%
EPS Next 3Y22.49%
EPS Next 5Y15.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1063.28%
Revenue Next 2Y222.93%
Revenue Next 3Y271.98%
Revenue Next 5Y160.56%
EBIT growth 1Y1.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.53%
OCF growth 3YN/A
OCF growth 5YN/A